Last hope? new combo targets AML that beat venetoclax
NCT ID NCT04926285
First seen Mar 24, 2026 · Last updated May 22, 2026 · Updated 7 times
Summary
This early-phase study tested a combination of two drugs (venetoclax and omacetaxine) in 6 adults with acute myeloid leukemia (AML) whose cancer had stopped responding to venetoclax. The goal was to find a safe dose and see if the combo could shrink the cancer. The study was small and completed, but results are not yet widely available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.